Becton Dickinson & Co. Upgraded to Overweight by Piper Jaffray (BDX)
Becton Dickinson & Co. (NYSE:BDX) was upgraded by equities research analysts at Piper Jaffray to an “overweight” rating in a research note issued to investors on Tuesday, Analyst Ratings Network.com reports. The firm currently has a $18.00 target price on the stock. Piper Jaffray’s price objective would suggest a potential downside of 83.83% from the company’s current price.
A number of other firms have also recently commented on BDX. Analysts at Barclays raised their price target on shares of Becton Dickinson & Co. from $106.00 to $112.00 in a research note to investors on Thursday, January 9th. They now have an “underweight” rating on the stock. Separately, analysts at Merrill Lynch upgraded shares of Becton Dickinson & Co. to a “neutral” rating in a research note to investors on Tuesday, January 7th. Finally, analysts at Bank of America Corp. upgraded shares of Becton Dickinson & Co. from an “underperform” rating to a “neutral” rating in a research note to investors on Tuesday, January 7th. They now have a $95.00 price target on the stock, down previously from $117.00. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $103.39.
Becton Dickinson & Co. (NYSE:BDX) traded down 0.13% on Tuesday, hitting $111.17. The stock had a trading volume of 338,209 shares. Becton Dickinson & Co. has a 52-week low of $82.72 and a 52-week high of $112.71. The stock has a 50-day moving average of $109.1 and a 200-day moving average of $103.9. The company has a market cap of $21.577 billion and a P/E ratio of 17.13.
Becton Dickinson & Co. (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.46 by $0.06. The company had revenue of $2.10 billion for the quarter, compared to the consensus estimate of $2.05 billion. During the same quarter in the prior year, the company posted $1.42 earnings per share. The company’s quarterly revenue was up 6.8% on a year-over-year basis. On average, analysts predict that Becton Dickinson & Co. will post $6.22 earnings per share for the current fiscal year.
Becton, Dickinson and Company (NYSE:BDX) is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.